Navigation Links
Icahn Indicates That Biogen Board Refuses To Close Polls
Date:6/3/2009

NEW YORK, June 3 /PRNewswire/ -- Carl Icahn announced today that Biogen is acting in its usual shareholder unfriendly way by manipulating the annual meeting of shareholders in order the prevent the votes that have been submitted from being counted. They are doing so in order to attempt to keep two of the Icahn nominees from winning seats on the Board. If the Board is successful, Richard Mulligan, a prominent scientist and physician, may be kept from legitimately being elected to the Board. This is a consistent theme of this Board. Do everything possible to keep shareholders from entering into the Board's private club to ensure that shareholders are kept in the dark about what the Board is doing, just as they were about last year's sale process. Mr. Icahn concluded that "shareholders should demand that this Board finally act in their interest instead of just attempting to relect themselves. There is absolutely no reason to adjourn the meeting for hours in order to keep the polls open. Do not let them get away with hijacking the election."


'/>"/>
SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Issues Statement in Response to Carl Icahn
2. Icahn Asks Amylin to Allow Discussions With Eastbourne
3. Icahn Responds to Cornelius
4. Icahn Confirms Intention to Nominate Three Directors at Biogen
5. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
6. New study indicates smallpox vaccination effective for decades
7. New study indicates smallpox vaccination effective for decades
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
10. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
11. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... FOLD ) today announced the election of ... Dr. Barer currently serves as Chairman and Chief ... veteran, Dr. Barer brings over 20 years of management ... leader who has helped transform Celgene into one of ...
... BURLINGTON, Mass., Jan. 8 Palomar Medical Technologies, ... researcher and developer of light-based systems for cosmetic ... distribution agreement with the Swedish company Q-MED AB ... biotech/medical device company based in Uppsala, Sweden. ...
... AMGN ) will present at the 27th Annual ... on Monday, Jan. 12, 2009, at the Westin St. Francis ... Sharer will present at the conference. Live audio of the ... accessed from Amgen,s Web site, www.amgen.com , under Investors. ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... of death in Europe and early diagnosis is essential ... electrical activity in real time using an electrocardiogram (ECG) ... the nature of a problem. Some cardiac conditions need ... them to be away from their everyday environment for ...
... Research engineers and sleep medicine specialists from two ... to put innovative quantitative analysis, signal-processing technology and ... One of their recent findings is that ... to distinguish fibromyalgia patients from healthy controls. ...
... given quercetin, a naturally occurring substance found in fruits ... according to a study published by The American Physiological ... the susceptibility of mice to the flu, but quercetin ... chemical relative of resveratrol, is present in a variety ...
Cached Biology News:A home early warning system for cardiac patients 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Substance found in fruits and vegetables reduces likelihood of the flu 2Substance found in fruits and vegetables reduces likelihood of the flu 3
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
... in immunostaining ,This solution has effect on ... get clearer signal than the one obtained ... amount of secondary antibody used and exposure ... can have images with high S/N ratio ...
Biology Products: